The CDC GLP-1 survey found that about 1 in 10 U.S. adults reported using one of these medicines in the past year. Among users, about 1 in 5 reported a compounded version, prepared by a pharmacy. About 2 in 5 changed how they took their medicine. Those figures describe behavior, not proof that changing a prescription is safe.
GLP-1 medicines copy gut-hormone signals involved in appetite and blood sugar. Semaglutide is one example; CDC also counted tirzepatide and several other medicines.
Promise is a telehealth company through which compounded GLP-1 medication is prescribed, so it has a commercial interest in this subject.
What the CDC GLP-1 survey found
As of November 20, 2026, the day this article was written, CDC's November 12 MMWR report offers a national snapshot of use during 2025. MMWR is CDC's Morbidity and Mortality Weekly Report. Samantha Pierce and colleagues analyzed 8,118 adults surveyed in July–August 2025 through CDC's Rapid Surveys System.
Overall, 976 respondents reported use in the previous year. After CDC adjusted answers to reflect the national population, the estimate was 9.8% of adults.
| Group | Reported GLP-1 use in the past year |
|---|---|
| Women | 11.9% |
| Men | 7.6% |
| Ages 18–39 | 4.8% |
| Ages 40–64 | 13.7% |
| Ages 65 and older | 11.1% |
Use was also more common among adults reporting a diabetes diagnosis: 47.4%, compared with 5.7% among those without one. These are health-history comparisons, not a record of why each prescription was written.
Compounded users reported more changes
Among GLP-1 users, 22.6% reported a compounded version; another 8.8% did not know whether their medicine was compounded.
Changing use was more common among compounded users: 62%, compared with 36% among those not reporting compounded use. The report states that compounded GLP-1 medications “are not reviewed by FDA for safety, effectiveness, or quality before they are marketed.” It adds that FDA and the American Diabetes Association have raised concerns about the safety, quality and effectiveness of compounded GLP-1s, and that analyses of FDA adverse-event reports found disproportionately higher reporting of preparation errors, contamination and manufacturing issues for compounded products than for noncompounded ones.
The authors discuss cost, shortages and limited insurance coverage as access barriers. Among users who modified treatment, 38% cited cost and 36% availability. Those findings do not establish why the compounded and noncompounded groups differed. A survey cannot show that compounded products caused the difference.
Across all users, 44% reported modifying use, with skipping doses the most common change at 28%. About 12% reported reducing or stopping medication because of side effects or symptoms. Modification was reported by 54% of users aged 18–39, versus 30% of those 65 and older.
The separate guides to compounded semaglutide and compounded tirzepatide explain those preparations. CDC's combined figures do not show whether semaglutide users changed treatment more often than tirzepatide users.
What this survey cannot tell us
This was a self-reported 2025 snapshot, not a count of current use in November 2026. People recalled their medication use; researchers did not observe injections or verify each dose.
The two online panels had low cumulative response rates: 13.3% for AmeriSpeak and 3.8% for KnowledgePanel. Those are different from the survey completion rate of 62.6%. CDC used weighting, an adjustment giving some answers more influence, to match national totals from the National Health Interview Survey. That helps address who responded; it cannot remove recall errors.
The report counted behavior, not health outcomes after those changes. It does not show that skipping, stretching or splitting doses is safe. The GLP-1 cost and adherence study examines prescription refills, a different measure from what people say they took.
Missed-dose labels describe specific situations
Changing a dose or restarting after a gap is a prescriber decision. Brand directions are not interchangeable with directions for a compounded prescription.
As of November 20, 2026, the day this article was written, the Wegovy label reads “Revised: 06/2026”; the Zepbound label reads “Revised: 11/2026.” Their missed-dose rules differ.
Wegovy injection, containing semaglutide: when the next scheduled dose is “More than 2 days away,” the label directs administering the missed injection as soon as possible. When it is “Less than 2 days away,” the label says not to administer the missed injection and to resume the regular day. After “2 or more consecutive doses” are missed, it directs “reinitiate dosage escalation at a lower dosage.” That means starting lower and increasing gradually to reduce digestive side effects.
Zepbound, containing tirzepatide: the label directs giving a missed dose “as soon as possible within 4 days (96 hours) after the missed dose.” After “more than 4 days,” it directs skipping that dose and resuming on the regularly scheduled day. If the weekly day is changed, the label requires at least “3 days (72 hours)” between doses. It gives no separate schedule for restarting after several missed weekly doses; the prescriber determines that plan.
As of November 20, 2026, the day this article was written, FDA's November 9 safety communication requires a warning about a rare eye condition that can cause permanent vision loss. FDA says to contact a health care professional right away for sudden painless vision loss, blurred or missing vision, distorted colors, or reduced central sharpness. These symptoms need that response, not an improvised dose change.
Knowing which medicine was dispensed
A pharmacy dispensing label identifies the pharmacy. Someone unsure whether their medicine is compounded can ask that pharmacy or the prescriber directly.
A separate 2025 study in JAMA Health Forum found that 11 of 79 websites did not disclose that their GLP-1 products were compounded. CDC's report says the share of users who were unsure potentially reflects how hard it is to distinguish compounded products from approved brand-name ones, and it cites the same website study in that discussion.
Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.
A licensed provider may still prescribe — that decision is between you and your doctor.
What to watch next
The next useful studies would track what happens after people modify treatment: symptoms, blood sugar, weight and medication errors. They would distinguish changes agreed with a prescriber from changes made without one. CDC's report raises those questions; it does not answer them.
For someone facing a refill problem or side effects, the practical conversation is what happened, which medicine was dispensed and what the prescriber plans next. A percentage from a survey cannot set that plan.
At Promise, a licensed provider reviews every request, and not everyone qualifies.





